MedTrace Logo

Ruxolitinib in Seborrheic Dermatitis

NCT05787860 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2025-05-06

Study results available
· View outcomes & findings →

Summary

This study is an open-label prospective interventional trial that will assess the efficacy of ruxolitinib in the treatment of seborrheic dermatitis. It will also attempt to characterize the molecular immune profiles of patients with SD at week 0 and week 4, with comparison to baseline profiles in healthy control subjects.

Conditions

  • Seborrheic Dermatitis

Interventions

DRUG

Ruxolitinib 1.5% Cream

topical ruxolitinib 1.5% cream twice daily for 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Benjamin Ungar, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-15
Primary Completion
2024-01-26
Completion
2024-01-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05787860 on ClinicalTrials.gov